Why the study?
No-reflow is associated with worse outcomes after STEMI, but the relationship between autoantibodies activating endothelin-1 receptor type A and no-reflow after PPCI was unclear.
Is ETAR-AA seropositivity associated with no-reflow (microvascular obstruction) in STEMI patients after primary PCI?
Is ETAR-AA seropositivity associated with no-reflow (microvascular obstruction) in STEMI patients after primary PCI?
Answers are grounded in this paper and cite their sources.
Elevated levels of autoantibodies targeting endothelin type-A receptors are independently associated with microvascular obstruction in STEMI patients after primary PCI, suggesting a potential novel biomarker for no-reflow.
BACKGROUND AND AIMS: No-reflow (NR), where the coronary artery is patent after treatment of ST-elevation myocardial infarction (STEMI) but tissue perfusion is not restored, is associated with worse outcomes. We aimed to investigate the relationship between autoantibodies activating endothelin-1 receptor type A (ETAR-AAs) and NR after primary percutaneous coronary intervention (PPCI) in STEMI. METHODS: We studied 50 patients (age 59 ± 11 years, 40 males) with STEMI who underwent PPCI within 6 h after the onset of symptoms. Blood samples were obtained from all patients within 12 h following PPCI for ETAR-AA level measurement. The seropositive threshold was provided by the manufacturer (>10 U/ml). NR was assessed by cardiac magnetic resonance imaging (MVO, microvascular obstruction). As a control group, 40 healthy subjects matched for age and sex were recruited from the general population. RESULTS: MVO was observed in 24 patients (48%). The prevalence of MVO was higher in patients with ETAR-AAs seropositivity (72% vs. 38%, p = 0.03). ETAR-AAs were higher in patients with MVO (8.9 U/mL (interquartile range [IQR] 6.8-16.2 U/mL) vs. 5.7 U/mL [IQR 4.3-7.7 U/mL], p = 0.003). ETAR-AAs seropositivity was independently associated with MVO (OR 3.2, 95% CI 1.3-7.1; p = 0.03). We identified ≥6.74 U/mL as the best cut-off for prediction of MVO (sensitivity 79%; specificity 65%; NPV 71%; PPV 74%; accuracy 72%). CONCLUSIONS: The ETAR-AAs seropositivity is associated with NR in STEMI patients. These findings may open up new options in the management of myocardial infarction even if confirmation in a larger trial is needed.
No takes yet. Share an insight, caveat, or question.
Tona et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: